Japan’s New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI
Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges.
You may also be interested in...
HBW Insight Exclusive: A lack of regulatory harmonization, especially with regards to Rx-to-OTC switch, is holding the Asia-Pacific OTC market back, according to APSMI secretary general, Toshi Tominaga.
GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.
Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview.